Online inquiry

IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3851MR)

This product GTTS-WQ3851MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL6R gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_000565.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3570
UniProt ID P08887
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3851MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ453MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 3G3
GTTS-WQ9449MR IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IPH4102
GTTS-WQ13865MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN-1979
GTTS-WQ7523MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GC-182
GTTS-WQ11841MR IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MK-4280
GTTS-WQ8041MR IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA H1H3592P3
GTTS-WQ6693MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ7835MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GSK-1223249
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW